BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CBX-250 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CBX-250\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06994676-2957@assetmemo.bio
DTSTAMP:20261121T005443Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:CBX-250: Phase 1 readout est. (NCT06994676)
DESCRIPTION:CBX-250\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study of 
 CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias\nEst
 imated primary completion: January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cbx-250#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06994676
URL:https://assetmemo.bio/drug/cbx-250#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
